Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 226

Results For "RAT"

7168 News Found

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
Diagnostic Center | August 13, 2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV


Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg
Drug Approval | August 13, 2024

Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals


Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
News | August 13, 2024

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland


Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Drug Approval | August 13, 2024

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years


Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
News | August 13, 2024

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP


Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
News | August 12, 2024

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore


Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
News | August 12, 2024

Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr

Revenue from operations stood at Rs. 313.4 crore during Q1 FY25


Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
News | August 12, 2024

Lupin Q1 FY25 profit up 77% at Rs. 801 Cr

Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore


Novo Nordisk's H1 sales increased by 24% in Danish kroner
News | August 12, 2024

Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER


Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical
News | August 11, 2024

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases